How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

931 results for

Human Papilloma Virus Vaccine

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Improving Human Papilloma Virus (HPV) Vaccine Uptake

Improving Human Papilloma Virus (HPV) Vaccine Uptake Improving Human Papilloma Virus (HPV) Vaccine Uptake A Rapid Review Region of Peel – Public Health Communicable Diseases Division October 2019 Please use the following citation when referencing this document: Region of Peel – Public Health. Improving Human Papilloma Virus (HPV) Vaccine Uptake: A rapid review. Mississauga, ON: Region of Peel – Public Health; 2019. Table of Contents KEY MESSAGES 1 EXECUTIVE SUMMARY 2 1 ISSUE 4 2 CONTEXT 5 3 (...) and meta-analysis of interventions to improve access and coverage of adolescent immunizations. J Adolesc Health. [Internet] Oct 2016 [cited July 29, 2019]; 59(4 Suppl): S40–S48. Available from: https://doi.org/10.1016/j.jadohealth.2016.07.005 13. Kang HS, De Gagne JC, Son YD & Chae SM. Completeness of human papilloma virus vaccination: a systematic review. J Pediatr Nurs. [Internet] Mar – Apr 2018 [cited July 29, 2019]; 39:7-14. Available from: https://doi.org/10.1016/j.pedn.2017.12.003 14. Niccolai LM

2020 Peel Health Library

2. Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope Full Text available with Trip Pro

Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope 29263867 2018 11 13 2059-0105 2 2017 NPJ vaccines NPJ Vaccines Inadvisable anti-vaccination sentiment: Human Papilloma Virus immunisation falsely under the microscope. 6 10.1038/s41541-017-0004-x Head Michael G MG Faculty of Medicine, University of Southampton, Southampton, UK. 0000 0004 1936 9297 grid.5491.9 Wind-Mozley Magdalen M Independent researcher, Newbury, UK. Flegg Peter J PJ (...) Department of Medicine, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, UK. grid.440172.4 eng Journal Article 2017 03 08 England NPJ Vaccines 101699863 2059-0105 2016 08 19 2016 10 10 2016 12 06 2017 12 22 6 0 2017 12 22 6 0 2017 12 22 6 1 epublish 29263867 10.1038/s41541-017-0004-x 4 PMC5627248 Vaccine. 2011 Oct 26;29(46):8279-84 21907257 Lancet Glob Health. 2016 Jul;4(7):e453-63 27340003 Lancet. 2015 Jun 27;385(9987):2571 26122153 J Adolesc Health. 2011 Nov;49(5):467-75 22018560 Vaccine

2017 NPJ Vaccines

3. The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus Full Text available with Trip Pro

The effect of history of abnormal pap smear or preceding HPV infection on the humoral immune response to Quadrivalent Human Papilloma virus (qHPV) vaccine in women with systemic lupus erythematosus To determine if natural human papillomavirus (HPV) infection would induce an anamnestic response to quadrivalent (qHPV) vaccine in women with Systemic Lupus Erythematosus (SLE).Thirty four women (19-50 years) with mild to moderate and minimally active or inactive SLE received standard qHPV vaccine (...) . Neutralizing antibody titers to HPV 6, 11, 16 and18 were evaluated pre- and post- vaccine using HPV competitive Luminex Immunoassay. For each HPV type, logistic regressions were performed to explore the relationship between a positive titer at baseline with their final geometric mean titer and with the rise in titer. Fisher's Exact Test was used to assess the association of at least one positive HPV antibody test at baseline and history of abnormal pap.History of abnormal pap smear/cervical neoplasia

2018 Human vaccines & immunotherapeutics

4. Vaccine-preventable Infections and Immunization in Multiple Sclerosis

to Poser 11 or McDonald 12 criteria. Initially, the panel included only cases of MS diagnosed by a neurologist but later revised this requirement because many studies used computerized databases. Accepted control group criteria varied by question. For questions referencing the general population, studies with only neurologic disease control groups were excluded. 11 The panel included immunizations recommended by the US Centers for Disease Control and Prevention (CDC) 13 and vaccines suggested (...) with 10 untreated participants with MS and 4 HCs (combined control group). All participants in the treated and untreated groups had baseline immunity to at least one of the 3 viral strains; 9/42 possible participant-variant combinations in the control group and 8/51 in the daclizumab-treated group did not fulfill criteria for seroprotection on day 0 (denominators represent the combination of antibodies to all 3 virus strains tested in the group). After treatment with a trivalent influenza vaccine

2019 American Academy of Neurology

5. Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2)

information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Keywords provided by Hospices Civils de Lyon: mucoviscidosis Human Papilloma Virus Vaccination Young girl Additional relevant MeSH terms: Layout table for MeSH terms Fibrosis Cystic Fibrosis Papilloma Pathologic Processes Pancreatic Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases Neoplasms, Squamous Cell Neoplasms (...) Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2) Human Papilloma Virus Vaccination in Girls With Cystic Fibrosis (VACCIN-HPV-MUC2) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding

2018 Clinical Trials

6. Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria Full Text available with Trip Pro

Human Papilloma Virus Vaccine Awareness and Vaccination History in Patients Attending STI Clinics in Lagos and Ibadan, Nigeria HPV is one of the most common causes of sexually transmitted disease in both men and women worldwide. It is transmitted through vaginal, anal, and oral sex. This study provided information on the Human Papilloma Virus (HPV) vaccine awareness and vaccination history in relation to the level of antibodies to (HPV) in the population at risk in Nigeria. Patients attending (...) STI clinics at Lagos and Ibadan were recruited and informed consent was obtained from all the participants. Using semi structured questionnaire, vaccination history, demography and past experiences of the patients were obtained. Whole blood samples were obtained and the sera screened for specific antibodies to HPV using ELISA test kits for determination of IgG to HPV by DIA PRO Diagnostic Bioprobes Milano-Italy according to the manufacturer's instruction. Of the170 samples analysed 50 (29.4

2018 Archives of basic and applied medicine

7. How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda Full Text available with Trip Pro

How Are New Vaccines Prioritized in Low-Income Countries? A Case Study of Human Papilloma Virus Vaccine and Pneumococcal Conjugate Vaccine in Uganda To date, research on priority-setting for new vaccines has not adequately explored the influence of the global, national and sub-national levels of decision-making or contextual issues such as political pressure and stakeholder influence and power. Using Kapiriri and Martin's conceptual framework, this paper evaluates priority setting for new (...) vaccines in Uganda at national and sub-national levels, and considers how global priorities can influence country priorities. This study focuses on 2 specific vaccines, the human papilloma virus (HPV) vaccine and the pneumococcal conjugate vaccine (PCV).This was a qualitative study that involved reviewing relevant Ugandan policy documents and media reports, as well as 54 key informant interviews at the global level and national and sub-national levels in Uganda. Kapiriri and Martin's conceptual

2017 International journal of health policy and management

8. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

with HIV and 9-valent HPV vaccine introduction Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction Technical guidance 30 Mar 2020 Cite: European Centre for Disease Prevention and Control. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction, 2020. Stockholm: ECDC; 2020. This guidance on human papilloma virus (HPV) vaccination in EU countries covers the following areas (...) not previously targeted by immunisation programmes: HIV-infected Data Evidence of the safety of the HPV vaccine in HIV-infected men and women Table - 30 Mar 2020 Efficacy, immunogenicity, safety and tolerability in other populations not previously targeted by immunisation programmes: HIV-infected men and women More on this topic Follow us: Footer Navigation © European Centre for Disease Prevention and Control (ECDC) 2020 Other sites: Search Search Search Search

2020 European Centre for Disease Prevention and Control - Technical Guidance

9. Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction

of healthcare and social support systems, national vaccination programmes and professional society organisations with an interest in HPV and/or immunisation programmes. Guidance on HPV vaccination in EU countries: focus on boys, PLHIV and 9-valent HPV vaccine introduction SCIENTIFIC ADVICE 4 2. Background Human papilloma virus is one of the most widespread and common sexually transmitted infections worldwide and is acquired soon after the start of sexual activity. The recognition of the central role of HPV (...) Assessment, Development and Evaluation HPV Human papilloma virus ICER Incremental cost-effectiveness ratio ICO Istituto Catala' d'Oncologia (Spain) LY Life years 9vHPV Nine-valent HPV vaccine PeIN Penile intraepithelial neoplasia PICO Population Intervention Comparison Outcome POTS Postural orthostatic tachycardia syndrome QALY Quality-adjusted life years 6MPI Six-month persistent infection VaIN Vaginal intraepithelial neoplasia VLP Virus-like particle VIN Vulvar intraepithelial neoplasia Glossary Cost

2020 European Centre for Disease Prevention and Control - Technical Guidance

10. Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. Full Text available with Trip Pro

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications. Few studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM).We described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV (...) believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.

2019 BMC Public Health

11. Knowledge towards human papilloma virus (HPV) infection and attitude towards its vaccine in the Kingdom of Bahrain: cross-sectional study. Full Text available with Trip Pro

Knowledge towards human papilloma virus (HPV) infection and attitude towards its vaccine in the Kingdom of Bahrain: cross-sectional study. To determine the level of awareness of human papilloma virus (HPV) infection and to assess attitudes towards receiving the vaccine among men and women in Bahrain.A cross-sectional study. An interview-based questionnaire was used to measure HPV knowledge and attitude towards HPV vaccine.Ten randomly selected primary health centres (PHCs) in the Kingdom (...) the community about the HPV infection.Despite the limited knowledge about HPV infection among the study's participants, there is a favourable attitude towards the HPV vaccine. These data can support the initiation of a nationwide HPV immunisation programme.© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

2019 BMJ open

12. Primary Ovarian Insufficiency and Human Papilloma Virus Vaccines: A Review of the Current Evidence. (Abstract)

Primary Ovarian Insufficiency and Human Papilloma Virus Vaccines: A Review of the Current Evidence. Human papilloma virus is the primary causative agent for cervical cancer, and vaccination is the primary means of preventing anogenital cancers caused by human papilloma virus infection. Despite the availability of human papilloma virus vaccines for over a decade, coverage rates lag behind the other vaccines. Public concerns regarding safety of human papilloma virus vaccines have been identified (...) as an important barrier to vaccination, including concerns that the human papilloma virus vaccine causes primary ovarian insufficiency, driven in part by isolated reports of ovarian failure following the human papilloma virus vaccine. We summarize published peer-reviewed literature on human papilloma virus vaccines and primary ovarian insufficiency reviewing information contained in the case reports and series. Health care providers should address any patient concerns about primary ovarian insufficiency

2019 American Journal of Obstetrics and Gynecology

13. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. Full Text available with Trip Pro

Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. In recurrent human papilloma virus (HPV)-driven cancer, immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies produces tumor regression in only a minority of patients. Therapeutic HPV vaccines have produced strong immune responses to HPV-16, but vaccination alone has been ineffective for invasive cancer.To (...) determine whether the efficacy of nivolumab, an anti-PD-1 immune checkpoint antibody, is amplified through treatment with ISA 101, a synthetic long-peptide HPV-16 vaccine inducing HPV-specific T cells, in patients with incurable HPV-16-positive cancer.In this single-arm, single-center phase 2 clinical trial, 24 patients with incurable HPV-16-positive cancer were enrolled from December 23, 2015, to December 12, 2016. Duration of follow-up for censored patients was 12.2 months through August 31, 2017

2018 JAMA oncology Controlled trial quality: uncertain

14. Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. (Abstract)

Human papilloma virus vaccination induces strong human papilloma virus specific cell-mediated immune responses in HIV-infected adolescents and young adults. The ability of a quadrivalent human papilloma virus (HPV)-16/18/6/11 virus-like particles vaccine (Gardasil) to elicit HPV-specific cell-mediated immune responses was evaluated in antiretroviral therapy (ART)-treated HIV-infected young adults. Results showed that, after three doses of vaccine, central memory and effector memory CD4 (...) (+) and CD8(+) T lymphocytes, as well as HPV-specific interleukin (IL)2(+)/CD4(+), interferon-gamma (IFN-γ(+))/CD4(+), IFN-γ(+)/CD8(+) and tumour necrosis factor-alpha (TNF-α)(+)/CD8(+) T lymphocytes and Perforin and Granzyme B secreting CD8(+) T lymphocytes were significantly increased. Notably, results obtained in HIV-infected patients were comparable to those seen in HIV-uninfected age-matched healthy controls.

2015 AIDS

15. Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study

Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study Human papilloma virus vaccination programs reduce health inequity in most scenarios: a simulation study | SCPHRP Publication Information Date of Publication 31/10/2012 Link

2012 Scottish Collaboration for Public Health Research & Policy

16. Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma Full Text available with Trip Pro

Human papilloma virus E1-specific T cell immune response is associated with the prognosis of cervical cancer patients with squamous cell carcinoma Cervical cancer is attributable to human papilloma virus (HPV) infection in the majority cases. E1, an HPV derived-protein, plays an important role in the initiation and development of cervical cancer. Our study aims to investigate the HPV E1-specific T cell response in patients with cervical squamous cell carcinoma (CSCC).A total of 66 CSCC patients (...) with FIGO stage IIB-IIIB and 60 healthy controls were enrolled. Enzyme-Linked ImmunoSpot (ELISPOT) assays was used to measure the HPV E1-specific T cell response in the peripheral blood of these patients before treatment. The patients were treated with chemotherapy and/or radiotherapy and followed up clinically for three years. The relationship between the T cell response, various clinical characteristics and the prognosis were studied with univariate analysis, multivariate analysis and survival curve

2018 Infectious agents and cancer

17. Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. (Abstract)

Quadrivalent human papilloma virus vaccine for the treatment of multiple warts: a retrospective analysis of 30 patients. Various therapeutic modalities have been implemented for wart treatment, with limited efficacy. Recently, resistant warts treated using quadrivalent human papilloma virus (HPV) vaccine have been reported, although original articles on the efficacy of quadrivalent HPV vaccine on warts are rare.We performed the present study to evaluate the efficacy of quadrivalent HPV vaccine (...) in the treatment of multiple warts.We retrospectively reviewed 30 patients from our centers. Patient demographics, clinical features such as duration of disease, number and location of lesions, therapeutic response, and adverse reactions were assessed.Regarding therapeutic response, 14 patients (46.67%) showed "Complete response", 5 (16.67%) showed "Partial response", and 11 (36.67%) showed "No response". There were no statistically significant differences in sex, age, disease duration, and lesion number

2018 Journal of Dermatological Treatment

18. Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens Full Text available with Trip Pro

Potent therapeutic efficacy of an alphavirus replicon DNA vaccine expressing human papilloma virus E6 and E7 antigens Cervical cancer develops as a result of infection with high-risk human papillomavirus (HPV) through persistent expression of early proteins E6 and E7. Our group pioneered a recombinant viral vector system based on Semliki Forest virus (SFV) for vaccination against cervical cancer. The most striking benefit of this alphavirus vector-based vaccine platform is its high potency. DNA (...) vaccines on the other hand, have a major advantage with respect to ease of production. In this study, the benefits associated with both SFV-based vaccines and DNA vaccines were combined with the development of a DNA-launched RNA replicon (DREP) vaccine targeting cervical cancer. Using intradermal delivery followed by electroporation, we demonstrated that DREP encoding for E6,7 (DREP-E6,7) induced effective, therapeutic antitumor immunity. While immunizations with a conventional DNA vaccine did

2018 Oncoimmunology

19. Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination Full Text available with Trip Pro

Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination Despite the high prevalences of Human Papilloma Virus (HPV) infections and cervical cancer in Nigeria, utilization of the HPV vaccine as a highly effective preventive measure remains low. The aim of this study was to find out the awareness and attitudes of caregivers to HPV infections and the factors that determine acceptance of an HPV vaccine for their pre (...) -adolescent girls.This was a cross-sectional descriptive study of 508 caregivers of female children in Enugu Nigeria. A semi-structured questionnaire was used to collect information on knowledge of HPV, cervical cancer as well HPV vaccine and its acceptance for pre-adolescent female children. The data was analysed using descriptive statistics.Five hundred and eight (508) caregivers of female children were interviewed. Less than half, 221,(43.5%) of them knew about HPV, among these, 163 knew how HPV

2018 Infectious agents and cancer

20. Retraction: Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin Full Text available with Trip Pro

Retraction: Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin This corrects the article DOI: 10.1038/srep36943.

2018 Scientific reports

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>